Clover Health Investments, CORP. /de: insider trades · United States · SEC (Form 4)

About Clover Health Investments, CORP. /de

Clover Health Investments, Corp. is a United States healthcare company listed on NASDAQ, focused on Medicare Advantage insurance and clinical decision-support technology. The company traces its public-market origin to 2019, when it was formed as a SPAC under the name Social Capital Hedosophia Holdings Corp. III, and it completed its business combination with Clover Health in January 2021. Clover describes itself as a remote-first company and does not maintain a traditional headquarters, although its principal executive office communications are handled through Jersey City, New Jersey. The core business is its Insurance segment, which offers Medicare Advantage PPO and HMO plans to eligible seniors across several U.S. states. Clover’s competitive proposition is built around Clover Assistant, a proprietary technology platform designed to bring more actionable clinical information into the physician workflow. The system synthesizes claims, chart, medication, diagnostic, and EHR data to help providers identify chronic conditions earlier, close care gaps, and improve disease management. In practice, Clover is not simply an insurer; it aims to use software and data to influence utilization, quality outcomes, and medical cost trend. From a positioning standpoint, Clover competes in the highly contested Medicare Advantage market, where scale, pricing discipline, provider relationships, and CMS quality scores matter materially. The company emphasizes wide-network PPO products and technology-enabled care management as differentiators, particularly in markets where traditional integrated-provider models are less dominant. That technology layer is central to Clover’s strategy because it provides a path to support member retention, improve cohort economics, and potentially widen margins over time. A key strategic extension is Counterpart Health, launched as a SaaS and tech-enabled services offering to commercialize Clover Assistant for external payors and providers serving the Medicare-eligible population. This gives Clover an additional growth avenue beyond its own insurance book, with the potential for higher-margin software-style economics if adoption scales. Recent developments have been important. In late February 2026, Clover reported full-year 2025 results showing strong revenue growth, continued membership expansion, and positive adjusted EBITDA for the year. Management also guided to potential full-year 2026 GAAP net income profitability, which is a notable milestone for an insurance-tech platform that has historically focused on scaling first and profits later. At the same time, investors should watch regulatory and reimbursement sensitivity, especially Medicare rate updates, CMS Star ratings, and the company’s ability to sustain Clover Assistant adoption and medical cost control.